1
|
Zeytinoğlu M, Çınaroğlu OS, Bora ES, Erbaş O. Healing with Love: Oxytocin Accelerates Oral Ulcer Recovery by Reducing Inflammation. J Clin Med 2025; 14:2667. [PMID: 40283497 PMCID: PMC12028035 DOI: 10.3390/jcm14082667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2025] [Revised: 04/09/2025] [Accepted: 04/10/2025] [Indexed: 04/29/2025] Open
Abstract
Background: Oral ulcerative mucositis (OUM) is a painful, inflammatory mucosa lesion that impairs quality of life. Despite available treatments, effective agents that promote faster healing and modulate inflammation are still needed. Oxytocin (OT), a neuropeptide with anti-inflammatory and antioxidant properties, may aid wound healing by regulating the remodeling of the extracellular matrix (ECM). This study investigates the effects of OT on oral ulcer healing in rats, focusing on its modulation of the MMP-2/TIMP-2 pathway. Methods: Acetic acid 70% was used as the oral mucosal ulcer inducer. Thirty-six Wistar albino rats were divided into control, oral ulcer + saline, and oral ulcer + OT (intraperitoneally for 15 days) groups. Histopathological, biochemical, and molecular analyses were performed. Buccal mucosa tissue was examined for TNF-α, TIMP-2, and MMP-2 levels via ELISA, while oxidative stress markers and pentraxin-3 (PTX3) were also assessed. Results: OT significantly preserved epithelial integrity and reduced fibrosis compared to the saline group (p < 0.001). TNF-α, MMP-2, PTX3, and malondialdehyde levels were significantly lower, while TIMP-2 levels were elevated in the OT-treated group (p < 0.01). Histopathological analysis confirmed reduced inflammation and enhanced tissue organization. Conclusions: OT accelerates oral ulcer healing by modulating inflammation, oxidative stress, and ECM remodeling via the MMP-2/TIMP-2 pathway. These findings highlight its potential as a therapeutic agent for managing mucosal injuries. Further clinical studies are warranted.
Collapse
Affiliation(s)
- Mert Zeytinoğlu
- Department of Oral, Dental and Maxillofacial Surgery, Faculty of Dentistry, Ege University, 35040 Bornova, Izmir, Türkiye;
| | - Osman Sezer Çınaroğlu
- Department of Emergency Medicine, Faculty of Medicine, Izmir Katip Çelebi University, 35620 Çiğli, Izmir, Türkiye;
| | - Ejder Saylav Bora
- Department of Emergency Medicine, Faculty of Medicine, Izmir Katip Çelebi University, 35620 Çiğli, Izmir, Türkiye;
| | - Oytun Erbaş
- Faculty of Medicine, BAMER, Biruni University, 34015 Zeytinburnu, Istanbul, Türkiye;
| |
Collapse
|
2
|
M Madawana A, Awang Nawi MA, Tang L, Hassan A, Khamis MF. Does Mouthwash Use Affect Oral Cancer Risk? A Comprehensive Systematic Review and Meta-Analysis. Cureus 2025; 17:e77123. [PMID: 39925579 PMCID: PMC11803482 DOI: 10.7759/cureus.77123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/08/2025] [Indexed: 02/11/2025] Open
Abstract
Studies indicate a strong correlation between the length and degree of alcohol and tobacco use and the risk of oral cancer (OC). However, there has been debate concerning the usage of mouthwashes and associated higher risk of OC for many years. The purpose of this study was to gain insight into how using mouthwash influenced the risk of OC. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol was used when searching the PubMed/MEDLINE, Scopus, and Web of Science databases. Observational studies that addressed the relationship between mouthwash use and OC and involved adult or older adult populations were included. The Newcastle-Ottawa Scale was employed to check the methodological quality, and random effects meta-analysis, along with other subgroup analyses and meta-regression, were utilized to synthesize quantitative data. Out of 5,132 papers identified, 15 case-control studies comprising 6,515 cases and 17,037 controls were included in the review. Seventeen effect measures from these 15 studies were included in the meta-analysis. For individuals who used mouthwash three or more times a day, the pooled OR for OC was 1.00 (95% CI: 0.79-1.26; n = 17 studies). Among those who had used mouthwash for more than 40 years, the OR was 1.30 (95% CI: 1.58-4.82; p = 0.05; n = 2 studies). Some studies suggest that frequent mouthwash use may increase the risk of OC. Given the biological plausibility of this link, we exercise caution in interpreting these findings. It is important to note the limited research on the frequency and duration of mouthwash use. Thus, for the strengthening of the evidence for a possible dose-response effect of mouthwashes on OC risk, we suggest that future research should be focused on the frequency, duration, and substance of mouthwashes in depth.
Collapse
Affiliation(s)
- Ashwini M Madawana
- School of Dental Sciences, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, MYS
| | | | - Liszen Tang
- School of Dental Sciences, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, MYS
| | - Akram Hassan
- School of Dental Sciences, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, MYS
| | - Mohd Fadhli Khamis
- School of Dental Sciences, Hospital Pakar Universiti Sains Malaysia, Kota Bharu, MYS
| |
Collapse
|
3
|
Elsaadany B, Anayb SM, Mashhour K, Yossif M, Zahran F. Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial). BMC Oral Health 2024; 24:645. [PMID: 38824583 PMCID: PMC11143556 DOI: 10.1186/s12903-024-04379-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Accepted: 05/16/2024] [Indexed: 06/03/2024] Open
Abstract
OBJECTIVES This study aimed to evaluate the preventive and therapeutic effects of rebamipide gargle in comparison with benzydamine in head and neck cancer patients undergoing radiotherapy with or without chemotherapy. MATERIALS AND METHODS Phase III randomized clinical trial was conducted from January 2021 till August 2022 on one hundred patients with head and neck cancer receiving high doses of radiotherapy. These patients were equally allocated into either rebamipide group or benzydamine group, The measured outcomes were the incidence of oral mucositis ≥ grade1, according to the WHO mucositis scale, in addition to the duration, and the onset of oral mucositis. RESULTS There was no statistically significant difference between the two groups, regarding the incidence of a severe grade of oral mucositis (WHO grades 3), as well as the onset and duration of oral mucositis. Both gargles succeeded to prevent the development of WHO grade 4 oral mucositis. Side effects reported were mainly burning sensation in benzydamine group and nausea in rebamipide group. CONCLUSION Rebamipide mouthwash was as beneficial as benzydamine mouthwash in minimizing the incidence of severe oral mucositis induced by treatment of head and neck cancer. However, rebamipide gargle proved to be superior to benzydamine in terms of reduction in the severity of the radiation-induced oral mucositis. TRIAL REGISTRATION The trial was registered in the protocol Registration and Result system of Clinical Trials (Registration ID: NCT04685395)0.28-12-2020.
Collapse
Affiliation(s)
- Basma Elsaadany
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt.
| | - Samah M Anayb
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt
| | - Karim Mashhour
- Clinical Oncology, Kasr El Ainy- Cairo University, Cairo, Egypt
| | | | - Fat'heya Zahran
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt
| |
Collapse
|
4
|
Czarnowski M, Słowińska M, Sawieljew M, Wnorowska U, Daniluk T, Król G, Karasiński M, Okła S, Savage PB, Piktel E, Bucki R. Efficacy of Ceragenins in Controlling the Growth of Oral Microorganisms: Implications for Oral Hygiene Management. Pharmaceuticals (Basel) 2024; 17:204. [PMID: 38399419 PMCID: PMC10893225 DOI: 10.3390/ph17020204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 01/23/2024] [Accepted: 01/29/2024] [Indexed: 02/25/2024] Open
Abstract
Ensuring proper dental hygiene is of paramount importance for individuals' general well-being, particularly for patients receiving medical care. There is a prevailing utilization of conventional oral hygiene items, including toothbrushes and mouthwashes, which have gained widespread acceptance; nevertheless, their limitations encourage investigating novel options in this domain. Our study indicates that ceragenins (CSAs) being lipid analogs of host defense peptides, well-recognized for their wide-ranging antimicrobial properties, may be a potentially efficacious means to augment oral hygiene in hospitalized individuals. We demonstrate that ceragenins CSA-13, CSA-44, and CSA-131 as well as undescribed to date CSA-255 display potent antimicrobial activities against isolates of fungi, aerobic, and anaerobic bacteria from Candida, Streptococcus, Enterococcus, and Bacteroides species, which are well-recognized representatives of microbes found in the oral cavity. These effects were further confirmed against mono- and dual-species fungal and bacterial biofilms. While the ceragenins showed similar or slightly diminished efficacy compared to commercially available mouthwashes, they demonstrated a highly favorable toxicity profile toward host cells, that may translate into better maintenance of host mucosal membrane stability. This suggests that incorporating ceragenins into oral hygiene products could be a valuable strategy for reducing the risk of both oral cavity-localized and secondary systemic infections and for improving the overall health outcomes of individuals receiving medical treatment.
Collapse
Affiliation(s)
- Michał Czarnowski
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| | - Monika Słowińska
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| | - Mariusz Sawieljew
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| | - Urszula Wnorowska
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| | - Tamara Daniluk
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| | - Grzegorz Król
- Institute of Medical Science, Collegium Medicum, Jan Kochanowski University of Kielce, 25-317 Kielce, Poland; (G.K.); (S.O.)
| | - Maciej Karasiński
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| | - Sławomir Okła
- Institute of Medical Science, Collegium Medicum, Jan Kochanowski University of Kielce, 25-317 Kielce, Poland; (G.K.); (S.O.)
- Holy Cross Cancer Center, 25-734 Kielce, Poland
| | - Paul B. Savage
- Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA;
| | - Ewelina Piktel
- Independent Laboratory of Nanomedicine, Medical University of Białystok, 15-222 Białystok, Poland;
| | - Robert Bucki
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland; (M.C.); (M.S.); (M.S.); (U.W.); (T.D.); (M.K.)
| |
Collapse
|
5
|
Hamidi SP, Koohi-Hosseinabadi O, Khaksar S, Ghanbariasad A, Dehghanian AR, Dehghan A, Haddadi Z, Gorgin R, Farjam M, Alipanah H. Evaluation of the topical gel and oral administration of Punica Granatum Var Pleniflora on oral mucositis induced by 5-Fluorouracil in golden hamsters. BMC Complement Med Ther 2023; 23:225. [PMID: 37420236 DOI: 10.1186/s12906-023-04053-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 06/24/2023] [Indexed: 07/09/2023] Open
Abstract
BACKGROUND Oral mucositis (OM), an acute inflammation of the oral cavity, is a common complication in patients undergoing invasive myeloblastic chemotherapy or radiation therapy. 5-fluorouracil (5-FU) is one of the most effective therapeutic drugs, but one of the common side effects of 5-FU administration is OM. Unfortunately, no suitable treatment has been found, so far to control its side effects. Studies showed that herbal medicine like Punica granatum var pleniflora (PGP) has medicinal properties such as anti-inflammatory and antibacterial and can be an alternative for the treatment of fungal infection. Accordingly, we decided to investigate the therapeutic effect of PGP in the treatment of OM caused by 5-FU in golden hamsters. METHODS Sixty male golden hamsters were divided into six main group. Chemotherapy with 5-FU at dose of 60 mg/kg was performed at a ten-day duration. Then, cheek pouches of the hamsters were scratched with an 18-gauge sterile needle to induce oral mucositis in animals. On the twelfth day, as a day of intensification of OM, treatment with PGP including topical gel with concentrations of 5% and 10% and oral administration of hydro-alcoholic extract with doses of 125 mg/kg and 250 mg/kg for three- and five-day therapeutic duration were separately started. Finally, samples of cheek pouches in hamsters were collected on 14th and 17th days and histopathologic score (HPS), malondialdehyde (MDA), and myeloperoxidase (MPO) levels were assayed. RESULTS A significant (p < 0.05) decrease in histopathologic score was observed in G10%-, P125-treated groups in comparison to the Ctrl group. Our data showed that treatment with G10% is more potent than P125-treated group. In contrast, histopathologic score in G10%, P125, and P250 treated groups demonstrated almost similar values On the 17th day. However, the levels of MDA and MPO in the treatment groups were enhanced compared with control group (p < 0.05). CONCLUSIONS It is possible that PGP can play protective role in the healing of tissue damage caused by chemotherapy with 5-FU due to the presence of its natural compounds and antioxidant properties.
Collapse
Affiliation(s)
| | | | - Sepideh Khaksar
- Department of Plant Sciences, Faculty of Biological Sciences, Alzahra University, Tehran, Iran
| | - Ali Ghanbariasad
- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran
- Surgical and Clinical Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Amir Reza Dehghanian
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
| | - Azizallah Dehghan
- Surgical and Clinical Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Zahra Haddadi
- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
| | - Roxana Gorgin
- Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
| | - Mojtaba Farjam
- Surgical and Clinical Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.
| | - Hiva Alipanah
- Surgical and Clinical Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Physiology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
| |
Collapse
|
6
|
Ősz BE, Jîtcă G, Sălcudean A, Rusz CM, Vari CE. Benzydamine-An Affordable Over-the-Counter Drug with Psychoactive Properties-From Chemical Structure to Possible Pharmacological Properties. Pharmaceuticals (Basel) 2023; 16:ph16040566. [PMID: 37111323 PMCID: PMC10144213 DOI: 10.3390/ph16040566] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 04/03/2023] [Accepted: 04/07/2023] [Indexed: 04/29/2023] Open
Abstract
Benzydamine is a non-steroidal anti-inflammatory drug with distinct pharmacological properties from other compounds in the same therapeutic class. The differences are structural and pharmacological in nature; the anti-inflammatory mechanism is not strictly explained by the ability to interfere with the synthesis of prostaglandins. The compound is used strictly in local inflammatory diseases (inflammation in the oral and vaginal mucosa). In addition to the therapeutic indications found in the summary of product characteristics (SPC), the compound is used, in high doses, as a psychotropic substance for oral administration, having similar properties to lysergic acid diethylamide (LSD). As an over-the-counter (OTC) compound, it is easy to obtain, and the consequences of using it for purposes other than those assumed by the manufacturer raise various concerns. The reasons are related to the pharmacodynamic and pharmaco-toxicological properties, since neither the mechanism of action nor the possible side effects that would result from systemic consumption, in high doses, even occasionally, have been fully elucidated. The present review aims to analyze the pharmacodynamic properties of benzydamine, starting from the chemical structure, by comparison with structurally similar compounds registered in therapy (as an anti-inflammatory or analgesic) or used for recreational purposes.
Collapse
Affiliation(s)
- Bianca-Eugenia Ősz
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania
| | - George Jîtcă
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania
| | - Andreea Sălcudean
- Department of Ethics and Social Sciences, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania
| | - Carmen Maria Rusz
- Doctoral School of Medicine and Pharmacy, I.O.S.U.D, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540139 Targu Mures, Romania
| | - Camil-Eugen Vari
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540139 Targu Mures, Romania
| |
Collapse
|